Albemarle (ALB) PT Raised to $162.00 at Jefferies Group

Albemarle (NYSE:ALB) had its price objective raised by Jefferies Group from $156.00 to $162.00 in a research report sent to investors on Tuesday, November 14th. Jefferies Group currently has a buy rating on the specialty chemicals company’s stock. Jefferies Group also issued estimates for Albemarle’s Q4 2017 earnings at $1.19 EPS and FY2017 earnings at $4.45 EPS.

ALB has been the subject of a number of other research reports. BidaskClub lowered Albemarle from a buy rating to a hold rating in a research report on Saturday, August 12th. UBS boosted their price objective on Albemarle from $123.00 to $150.00 and gave the company a neutral rating in a research report on Thursday, November 9th. BMO Capital Markets assumed coverage on Albemarle in a research report on Tuesday, October 24th. They set an outperform rating and a $160.00 price objective for the company. Vertical Research restated a hold rating and set a $109.00 price objective (up previously from $108.00) on shares of Albemarle in a research report on Thursday, August 10th. Finally, Royal Bank Of Canada reiterated a buy rating and set a $136.00 price target on shares of Albemarle in a research report on Wednesday, September 20th. Ten analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Albemarle currently has an average rating of Buy and an average price target of $128.45.

Shares of Albemarle (NYSE ALB) traded down $2.17 during trading hours on Tuesday, hitting $132.15. The company had a trading volume of 1,240,091 shares, compared to its average volume of 1,234,781. The company has a current ratio of 2.11, a quick ratio of 1.56 and a debt-to-equity ratio of 0.35. Albemarle has a 1-year low of $84.37 and a 1-year high of $144.99. The stock has a market cap of $14,602.05, a P/E ratio of 32.71, a P/E/G ratio of 2.00 and a beta of 1.70.

Albemarle (NYSE:ALB) last issued its quarterly earnings results on Wednesday, November 8th. The specialty chemicals company reported $1.08 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.07 by $0.01. Albemarle had a return on equity of 11.61% and a net margin of 30.07%. The business had revenue of $755.00 million during the quarter, compared to the consensus estimate of $732.19 million. During the same period in the previous year, the business earned $0.91 EPS. The business’s quarterly revenue was up 15.4% on a year-over-year basis. equities research analysts expect that Albemarle will post 4.46 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Tuesday, January 2nd. Stockholders of record on Friday, December 15th will be given a dividend of $0.32 per share. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.97%. The ex-dividend date is Thursday, December 14th. Albemarle’s dividend payout ratio (DPR) is presently 16.56%.

Several institutional investors have recently made changes to their positions in the company. Cornerstone Advisors Inc. raised its position in Albemarle by 26.8% during the second quarter. Cornerstone Advisors Inc. now owns 1,751 shares of the specialty chemicals company’s stock valued at $185,000 after buying an additional 370 shares during the period. Baillie Gifford & Co. raised its position in Albemarle by 100.8% during the second quarter. Baillie Gifford & Co. now owns 184,555 shares of the specialty chemicals company’s stock valued at $19,478,000 after buying an additional 92,650 shares during the period. Meiji Yasuda Asset Management Co Ltd. acquired a new position in Albemarle during the second quarter valued at $439,000. Lord Abbett & CO. LLC acquired a new position in Albemarle during the second quarter valued at $11,681,000. Finally, Sumitomo Life Insurance Co. acquired a new position in Albemarle during the third quarter valued at $1,703,000. 87.85% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This story was first reported by BBNS and is the property of of BBNS. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. & international trademark and copyright laws. The original version of this story can be viewed at https://baseballnewssource.com/markets/albemarle-corporation-alb-price-target-raised-to-162-00-at-jefferies-group-llc/1782854.html.

About Albemarle

Albemarle Corporation is a global developer, manufacturer and marketer of highly-engineered specialty chemicals. The Company operates through three segments: Lithium and Advanced Materials, Bromine Specialties and Refining Solutions. Lithium and Advanced Materials segment consist of two product categories: Lithium and Performance Catalyst Solutions.

Analyst Recommendations for Albemarle (NYSE:ALB)

Receive News & Ratings for Albemarle Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albemarle Co. and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.